At its July 23-24, 2026 meeting, the FDAs Pharmacy Compounding Advisory Committee reviews seven peptides for 503A eligibility: on July 23, BPC-157, KPV, TB-500, and MOTS-C
The rationale is mechanistic non-overlap: rather than two compounds acting through the same pathway with redundant effects, BPC-157 and TB-500 engage distinct targets the former operating through nitric-oxide-pathway and VEGFR2 modulation, the latter through actin-cytoskeleton regulation
Glutathione levels decline with age, illness, toxin exposure, and chronic stress, and oral supplements barely make a dent
established a synergistic therapeutic strategy based on a thermosensitive in situ hydrogel consisting of poloxamer and hyaluronic acid, which allows the co-delivery of Fer-1 and antifungal agents